NowComment
2-Pane Combined
Comments:
Full Summaries Sorted

Commenting period (July 15, 2023 20:56 – August 16, 2023 00:00) is closed

ALS-02-v1


2 General Document comments
0 Sentence and Paragraph comments
0 Image and Video comments


1 RECOVER 2.0 Worksheet

Paragraph 1 0
No paragraph-level conversations.
Paragraph 1, Sentence 1 0
No sentence-level conversations.

2 QUESTION ID: ALS-02

Paragraph 2 0
No paragraph-level conversations.
Paragraph 2, Sentence 1 0
No sentence-level conversations.

3 PICO Question:
In cats and dogs with a shockable rhythm that are being defibrillated (P), does the use of amiodarone (I) compared to not using amiodarone (C) improve outcome?

Paragraph 3 0
No paragraph-level conversations.
Paragraph 3, Sentence 1 0
No sentence-level conversations.
Paragraph 3, Sentence 2 0
No sentence-level conversations.

4 Outcomes:
Favorable neurologic outcome, Surrogate marker(s) of perfusion, Survival to Discharge,ROSC

Paragraph 4 0
No paragraph-level conversations.
Paragraph 4, Sentence 1 0
No sentence-level conversations.
Paragraph 4, Sentence 2 0
No sentence-level conversations.

5 Prioritized Outcomes (1= most critical; final number = least important):

Paragraph 5 0
No paragraph-level conversations.
Paragraph 5, Sentence 1 0
No sentence-level conversations.

6 1. Favorable neurologic outcome

Paragraph 6 0
No paragraph-level conversations.
Paragraph 6, Sentence 1 0
No sentence-level conversations.
Paragraph 6, Sentence 2 0
No sentence-level conversations.

7 2. Survival to discharge

Paragraph 7 0
No paragraph-level conversations.
Paragraph 7, Sentence 1 0
No sentence-level conversations.
Paragraph 7, Sentence 2 0
No sentence-level conversations.

8 3. ROSC

Paragraph 8 0
No paragraph-level conversations.
Paragraph 8, Sentence 1 0
No sentence-level conversations.
Paragraph 8, Sentence 2 0
No sentence-level conversations.

9 4. Surrogate markers of perfusion

Paragraph 9 0
No paragraph-level conversations.
Paragraph 9, Sentence 1 0
No sentence-level conversations.
Paragraph 9, Sentence 2 0
No sentence-level conversations.

10 Domain chairs: Gareth Buckley, Elizabeth Rozanski (Fletcher), Jake Wolf

Paragraph 10 0
No paragraph-level conversations.
Paragraph 10, Sentence 1 0
No sentence-level conversations.

11 Evidence evaluators: Alexander Thomson, Joseph DeFulio

Paragraph 11 0
No paragraph-level conversations.
Paragraph 11, Sentence 1 0
No sentence-level conversations.

12 Conflicts of interest: None

Paragraph 12 0
No paragraph-level conversations.
Paragraph 12, Sentence 1 0
No sentence-level conversations.

13 Search strategy: See attached document

Paragraph 13 0
No paragraph-level conversations.
Paragraph 13, Sentence 1 0
No sentence-level conversations.

14 Evidence Review:

Paragraph 14 0
No paragraph-level conversations.
Paragraph 14, Sentence 1 0
No sentence-level conversations.

15 Study Design

Paragraph 15 0
No paragraph-level conversations.
Paragraph 15, Sentence 1 0
No sentence-level conversations.

16 Reduced Quality Factors

Paragraph 16 0
No paragraph-level conversations.
Paragraph 16, Sentence 1 0
No sentence-level conversations.

17 0 = no serious, - = serious,

Paragraph 17 0
No paragraph-level conversations.
Paragraph 17, Sentence 1 0
No sentence-level conversations.

18 - - = very serious

Paragraph 18 0
No paragraph-level conversations.
Paragraph 18, Sentence 1 0
No sentence-level conversations.

19 Positive Quality Factors

Paragraph 19 0
No paragraph-level conversations.
Paragraph 19, Sentence 1 0
No sentence-level conversations.

20 0 = none, + = one, ++ = multiple

Paragraph 20 0
No paragraph-level conversations.
Paragraph 20, Sentence 1 0
No sentence-level conversations.

21 Dichotomous Outcome Summary

Paragraph 21 0
No paragraph-level conversations.
Paragraph 21, Sentence 1 0
No sentence-level conversations.

22 Non-Dichotomous Outcome Summary

Paragraph 22 0
No paragraph-level conversations.
Paragraph 22, Sentence 1 0
No sentence-level conversations.

23 Brief description

Paragraph 23 0
No paragraph-level conversations.
Paragraph 23, Sentence 1 0
No sentence-level conversations.

24 Overall Quality

Paragraph 24 0
No paragraph-level conversations.
Paragraph 24, Sentence 1 0
No sentence-level conversations.

25 High, moderate, low,
very low, none

Paragraph 25 0
No paragraph-level conversations.
Paragraph 25, Sentence 1 0
No sentence-level conversations.
Paragraph 25, Sentence 2 0
No sentence-level conversations.

26 No of studies

Paragraph 26 0
No paragraph-level conversations.
Paragraph 26, Sentence 1 0
No sentence-level conversations.

27 Study Type

Paragraph 27 0
No paragraph-level conversations.
Paragraph 27, Sentence 1 0
No sentence-level conversations.

28 RoB

Paragraph 28 0
No paragraph-level conversations.
Paragraph 28, Sentence 1 0
No sentence-level conversations.

29 Indirectness

Paragraph 29 0
No paragraph-level conversations.
Paragraph 29, Sentence 1 0
No sentence-level conversations.

30 Imprecision

Paragraph 30 0
No paragraph-level conversations.
Paragraph 30, Sentence 1 0
No sentence-level conversations.

31 Inconsistency

Paragraph 31 0
No paragraph-level conversations.
Paragraph 31, Sentence 1 0
No sentence-level conversations.

32 Large Effect

Paragraph 32 0
No paragraph-level conversations.
Paragraph 32, Sentence 1 0
No sentence-level conversations.

33 Dose-Response

Paragraph 33 0
No paragraph-level conversations.
Paragraph 33, Sentence 1 0
No sentence-level conversations.

34 Confounder

Paragraph 34 0
No paragraph-level conversations.
Paragraph 34, Sentence 1 0
No sentence-level conversations.

35 # Intervention with Outcome

Paragraph 35 0
No paragraph-level conversations.
Paragraph 35, Sentence 1 0
No sentence-level conversations.

36 # Control with Outcome

Paragraph 36 0
No paragraph-level conversations.
Paragraph 36, Sentence 1 0
No sentence-level conversations.

37 RR (95% CI)

Paragraph 37 0
No paragraph-level conversations.
Paragraph 37, Sentence 1 0
No sentence-level conversations.

38 Outcome: Favorable neurologic outcome

Paragraph 38 0
No paragraph-level conversations.
Paragraph 38, Sentence 1 0
No sentence-level conversations.

39 3

Paragraph 39 0
No paragraph-level conversations.
Paragraph 39, Sentence 1 0
No sentence-level conversations.

40 CT

Paragraph 40 0
No paragraph-level conversations.
Paragraph 40, Sentence 1 0
No sentence-level conversations.

41 0

Paragraph 41 0
No paragraph-level conversations.
Paragraph 41, Sentence 1 0
No sentence-level conversations.

42 -

Paragraph 42 0
No paragraph-level conversations.
Paragraph 42, Sentence 1 0
No sentence-level conversations.

43 0

Paragraph 43 0
No paragraph-level conversations.
Paragraph 43, Sentence 1 0
No sentence-level conversations.

44 0

Paragraph 44 0
No paragraph-level conversations.
Paragraph 44, Sentence 1 0
No sentence-level conversations.

45 0

Paragraph 45 0
No paragraph-level conversations.
Paragraph 45, Sentence 1 0
No sentence-level conversations.

46 0

Paragraph 46 0
No paragraph-level conversations.
Paragraph 46, Sentence 1 0
No sentence-level conversations.

47 0

Paragraph 47 0
No paragraph-level conversations.
Paragraph 47, Sentence 1 0
No sentence-level conversations.

48 Moderate

Paragraph 48 0
No paragraph-level conversations.
Paragraph 48, Sentence 1 0
No sentence-level conversations.

49 2

Paragraph 49 0
No paragraph-level conversations.
Paragraph 49, Sentence 1 0
No sentence-level conversations.

50 OS

Paragraph 50 0
No paragraph-level conversations.
Paragraph 50, Sentence 1 0
No sentence-level conversations.

51 0

Paragraph 51 0
No paragraph-level conversations.
Paragraph 51, Sentence 1 0
No sentence-level conversations.

52 -

Paragraph 52 0
No paragraph-level conversations.
Paragraph 52, Sentence 1 0
No sentence-level conversations.

53 -

Paragraph 53 0
No paragraph-level conversations.
Paragraph 53, Sentence 1 0
No sentence-level conversations.

54 0

Paragraph 54 0
No paragraph-level conversations.
Paragraph 54, Sentence 1 0
No sentence-level conversations.

55 0

Paragraph 55 0
No paragraph-level conversations.
Paragraph 55, Sentence 1 0
No sentence-level conversations.

56 0

Paragraph 56 0
No paragraph-level conversations.
Paragraph 56, Sentence 1 0
No sentence-level conversations.

57 0

Paragraph 57 0
No paragraph-level conversations.
Paragraph 57, Sentence 1 0
No sentence-level conversations.

58 Very low

Paragraph 58 0
No paragraph-level conversations.
Paragraph 58, Sentence 1 0
No sentence-level conversations.

59 0

Paragraph 59 0
No paragraph-level conversations.
Paragraph 59, Sentence 1 0
No sentence-level conversations.

60 ES

Paragraph 60 0
No paragraph-level conversations.
Paragraph 60, Sentence 1 0
No sentence-level conversations.

61 Outcome: Survival to discharge

Paragraph 61 0
No paragraph-level conversations.
Paragraph 61, Sentence 1 0
No sentence-level conversations.

62 3

Paragraph 62 0
No paragraph-level conversations.
Paragraph 62, Sentence 1 0
No sentence-level conversations.

63 CT

Paragraph 63 0
No paragraph-level conversations.
Paragraph 63, Sentence 1 0
No sentence-level conversations.

64 0

Paragraph 64 0
No paragraph-level conversations.
Paragraph 64, Sentence 1 0
No sentence-level conversations.

65 -

Paragraph 65 0
No paragraph-level conversations.
Paragraph 65, Sentence 1 0
No sentence-level conversations.

66 0

Paragraph 66 0
No paragraph-level conversations.
Paragraph 66, Sentence 1 0
No sentence-level conversations.

67 0

Paragraph 67 0
No paragraph-level conversations.
Paragraph 67, Sentence 1 0
No sentence-level conversations.

68 0

Paragraph 68 0
No paragraph-level conversations.
Paragraph 68, Sentence 1 0
No sentence-level conversations.

69 0

Paragraph 69 0
No paragraph-level conversations.
Paragraph 69, Sentence 1 0
No sentence-level conversations.

70 0

Paragraph 70 0
No paragraph-level conversations.
Paragraph 70, Sentence 1 0
No sentence-level conversations.

71 Moderate

Paragraph 71 0
No paragraph-level conversations.
Paragraph 71, Sentence 1 0
No sentence-level conversations.

72 8

Paragraph 72 0
No paragraph-level conversations.
Paragraph 72, Sentence 1 0
No sentence-level conversations.

73 OS

Paragraph 73 0
No paragraph-level conversations.
Paragraph 73, Sentence 1 0
No sentence-level conversations.

74 0

Paragraph 74 0
No paragraph-level conversations.
Paragraph 74, Sentence 1 0
No sentence-level conversations.

75 -

Paragraph 75 0
No paragraph-level conversations.
Paragraph 75, Sentence 1 0
No sentence-level conversations.

76 -

Paragraph 76 0
No paragraph-level conversations.
Paragraph 76, Sentence 1 0
No sentence-level conversations.

77 -

Paragraph 77 0
No paragraph-level conversations.
Paragraph 77, Sentence 1 0
No sentence-level conversations.

78 0

Paragraph 78 0
No paragraph-level conversations.
Paragraph 78, Sentence 1 0
No sentence-level conversations.

79 0

Paragraph 79 0
No paragraph-level conversations.
Paragraph 79, Sentence 1 0
No sentence-level conversations.

80 0

Paragraph 80 0
No paragraph-level conversations.
Paragraph 80, Sentence 1 0
No sentence-level conversations.

81 Low

Paragraph 81 0
No paragraph-level conversations.
Paragraph 81, Sentence 1 0
No sentence-level conversations.

82 4

Paragraph 82 0
No paragraph-level conversations.
Paragraph 82, Sentence 1 0
No sentence-level conversations.

83 ES

Paragraph 83 0
No paragraph-level conversations.
Paragraph 83, Sentence 1 0
No sentence-level conversations.

84 0

Paragraph 84 0
No paragraph-level conversations.
Paragraph 84, Sentence 1 0
No sentence-level conversations.

85 -

Paragraph 85 0
No paragraph-level conversations.
Paragraph 85, Sentence 1 0
No sentence-level conversations.

86 -

Paragraph 86 0
No paragraph-level conversations.
Paragraph 86, Sentence 1 0
No sentence-level conversations.

87 -

Paragraph 87 0
No paragraph-level conversations.
Paragraph 87, Sentence 1 0
No sentence-level conversations.

88 0

Paragraph 88 0
No paragraph-level conversations.
Paragraph 88, Sentence 1 0
No sentence-level conversations.

89 0

Paragraph 89 0
No paragraph-level conversations.
Paragraph 89, Sentence 1 0
No sentence-level conversations.

90 0

Paragraph 90 0
No paragraph-level conversations.
Paragraph 90, Sentence 1 0
No sentence-level conversations.

91 Low

Paragraph 91 0
No paragraph-level conversations.
Paragraph 91, Sentence 1 0
No sentence-level conversations.

92 Outcome: ROSC

Paragraph 92 0
No paragraph-level conversations.
Paragraph 92, Sentence 1 0
No sentence-level conversations.

93 1

Paragraph 93 0
No paragraph-level conversations.
Paragraph 93, Sentence 1 0
No sentence-level conversations.

94 CT

Paragraph 94 0
No paragraph-level conversations.
Paragraph 94, Sentence 1 0
No sentence-level conversations.

95 0

Paragraph 95 0
No paragraph-level conversations.
Paragraph 95, Sentence 1 0
No sentence-level conversations.

96 -

Paragraph 96 0
No paragraph-level conversations.
Paragraph 96, Sentence 1 0
No sentence-level conversations.

97 0

Paragraph 97 0
No paragraph-level conversations.
Paragraph 97, Sentence 1 0
No sentence-level conversations.

98 0

Paragraph 98 0
No paragraph-level conversations.
Paragraph 98, Sentence 1 0
No sentence-level conversations.

99 0

Paragraph 99 0
No paragraph-level conversations.
Paragraph 99, Sentence 1 0
No sentence-level conversations.

100 0

Paragraph 100 0
No paragraph-level conversations.
Paragraph 100, Sentence 1 0
No sentence-level conversations.

101 0

Paragraph 101 0
No paragraph-level conversations.
Paragraph 101, Sentence 1 0
No sentence-level conversations.

102 Moderate

Paragraph 102 0
No paragraph-level conversations.
Paragraph 102, Sentence 1 0
No sentence-level conversations.

103 2

Paragraph 103 0
No paragraph-level conversations.
Paragraph 103, Sentence 1 0
No sentence-level conversations.

104 OS

Paragraph 104 0
No paragraph-level conversations.
Paragraph 104, Sentence 1 0
No sentence-level conversations.

105 0

Paragraph 105 0
No paragraph-level conversations.
Paragraph 105, Sentence 1 0
No sentence-level conversations.

106 -

Paragraph 106 0
No paragraph-level conversations.
Paragraph 106, Sentence 1 0
No sentence-level conversations.

107 0

Paragraph 107 0
No paragraph-level conversations.
Paragraph 107, Sentence 1 0
No sentence-level conversations.

108 0

Paragraph 108 0
No paragraph-level conversations.
Paragraph 108, Sentence 1 0
No sentence-level conversations.

109 0

Paragraph 109 0
No paragraph-level conversations.
Paragraph 109, Sentence 1 0
No sentence-level conversations.

110 0

Paragraph 110 0
No paragraph-level conversations.
Paragraph 110, Sentence 1 0
No sentence-level conversations.

111 0

Paragraph 111 0
No paragraph-level conversations.
Paragraph 111, Sentence 1 0
No sentence-level conversations.

112 Very low

Paragraph 112 0
No paragraph-level conversations.
Paragraph 112, Sentence 1 0
No sentence-level conversations.

113 7

Paragraph 113 0
No paragraph-level conversations.
Paragraph 113, Sentence 1 0
No sentence-level conversations.

114 ES

Paragraph 114 0
No paragraph-level conversations.
Paragraph 114, Sentence 1 0
No sentence-level conversations.

115 0

Paragraph 115 0
No paragraph-level conversations.
Paragraph 115, Sentence 1 0
No sentence-level conversations.

116 -

Paragraph 116 0
No paragraph-level conversations.
Paragraph 116, Sentence 1 0
No sentence-level conversations.

117 -

Paragraph 117 0
No paragraph-level conversations.
Paragraph 117, Sentence 1 0
No sentence-level conversations.

118 -

Paragraph 118 0
No paragraph-level conversations.
Paragraph 118, Sentence 1 0
No sentence-level conversations.

119 0

Paragraph 119 0
No paragraph-level conversations.
Paragraph 119, Sentence 1 0
No sentence-level conversations.

120 0

Paragraph 120 0
No paragraph-level conversations.
Paragraph 120, Sentence 1 0
No sentence-level conversations.

121 0

Paragraph 121 0
No paragraph-level conversations.
Paragraph 121, Sentence 1 0
No sentence-level conversations.

122 Very low

Paragraph 122 0
No paragraph-level conversations.
Paragraph 122, Sentence 1 0
No sentence-level conversations.

123 Outcome: Surrogate markers of perfusion

Paragraph 123 0
No paragraph-level conversations.
Paragraph 123, Sentence 1 0
No sentence-level conversations.

124 0

Paragraph 124 0
No paragraph-level conversations.
Paragraph 124, Sentence 1 0
No sentence-level conversations.

125 CT

Paragraph 125 0
No paragraph-level conversations.
Paragraph 125, Sentence 1 0
No sentence-level conversations.

126 0

Paragraph 126 0
No paragraph-level conversations.
Paragraph 126, Sentence 1 0
No sentence-level conversations.

127 OS

Paragraph 127 0
No paragraph-level conversations.
Paragraph 127, Sentence 1 0
No sentence-level conversations.

128 11

Paragraph 128 0
No paragraph-level conversations.
Paragraph 128, Sentence 1 0
No sentence-level conversations.

129 ES

Paragraph 129 0
No paragraph-level conversations.
Paragraph 129, Sentence 1 0
No sentence-level conversations.

130 0

Paragraph 130 0
No paragraph-level conversations.
Paragraph 130, Sentence 1 0
No sentence-level conversations.

131 -

Paragraph 131 0
No paragraph-level conversations.
Paragraph 131, Sentence 1 0
No sentence-level conversations.

132 -

Paragraph 132 0
No paragraph-level conversations.
Paragraph 132, Sentence 1 0
No sentence-level conversations.

133 -

Paragraph 133 0
No paragraph-level conversations.
Paragraph 133, Sentence 1 0
No sentence-level conversations.

134 0

Paragraph 134 0
No paragraph-level conversations.
Paragraph 134, Sentence 1 0
No sentence-level conversations.

135 0

Paragraph 135 0
No paragraph-level conversations.
Paragraph 135, Sentence 1 0
No sentence-level conversations.

136 0

Paragraph 136 0
No paragraph-level conversations.
Paragraph 136, Sentence 1 0
No sentence-level conversations.

137 Very low

Paragraph 137 0
No paragraph-level conversations.
Paragraph 137, Sentence 1 0
No sentence-level conversations.

138 PICO Question Summary

Paragraph 138 0
No paragraph-level conversations.
Paragraph 138, Sentence 1 0
No sentence-level conversations.

139 Introduction

Paragraph 139 0
No paragraph-level conversations.
Paragraph 139, Sentence 1 0
No sentence-level conversations.

140 The gold-standard for treatment of PVT and VF is basic life support and defibrillation. However, the role of adjunctive therapies for shock-resistant PVT or VF is unclear. Current veterinary guidelines state that in dogs with shock-resistant PVT or VF, amiodarone may be considered.1 In human medicine, the role of antiarrhythmics (amiodarone, lidocaine, bretylium, nifekalant, etc.) during CPR remains unclear. This PICO question investigated whether amiodarone is efficacious as adjunctive therapy in dogs and cats with shockable arrest rhythms.

Paragraph 140 0
No paragraph-level conversations.
Paragraph 140, Sentence 1 0
No sentence-level conversations.
Paragraph 140, Sentence 2 0
No sentence-level conversations.
Paragraph 140, Sentence 3 0
No sentence-level conversations.
Paragraph 140, Sentence 4 0
No sentence-level conversations.

141 Consensus on science

Paragraph 141 0
No paragraph-level conversations.
Paragraph 141, Sentence 1 0
No sentence-level conversations.

142 Outcome 1: Favorable neurologic outcome

Paragraph 142 0
No paragraph-level conversations.
Paragraph 142, Sentence 1 0
No sentence-level conversations.

143 For the most critical outcome of favorable neurologic outcome, 3 clinical trials in adult humans (moderate quality of evidence downgraded for serious indirectness) and 2 observational studies, one in children and one in adult humans, were identified (very low quality of evidence downgraded for serious indirectness and imprecision).2–6 The clinical trials were double-blinded and evaluated adults with non-traumatic out-of-hospital cardiac arrest and shock-refractory VF or PVT (defined as persistent or recurrent shockable rhythms after one or more shocks anytime during resuscitation). Patients were randomized to receive amiodarone, lidocaine, or placebo following vasopressor administration. Neither amiodarone nor lidocaine resulted in a more favorable neurologic outcome compared to placebo.2–4 The observational studies found no difference between lidocaine and amiodarone for favorable neurologic outcome with refractory PVT or VF; however, no control group was used in these studies.5,6 One study showed increased defibrillation success after 3 shocks in patients receiving amiodarone compared to patients receiving lidocaine.6

Paragraph 143 0
No paragraph-level conversations.
Paragraph 143, Sentence 1 0
No sentence-level conversations.
Paragraph 143, Sentence 2 0
No sentence-level conversations.
Paragraph 143, Sentence 3 0
No sentence-level conversations.

144 Outcome 2: Survival to discharge

Paragraph 144 0
No paragraph-level conversations.
Paragraph 144, Sentence 1 0
No sentence-level conversations.

145 For the second most critical outcome of survival to discharge, the same 3 clinical trials in adults were identified. In addition, 8 observational studies in humans (very low quality of evidence downgraded for serious indirectness) and four experimental studies in pigs (low quality of evidence downgraded for serious indirectness and imprecision) were identified.5–16 One of the clinical trials showed that for witnessed arrests, patients administered lidocaine or amiodarone had significantly higher survival to discharge when compared to placebo.3 Additionally, lidocaine and amiodarone recipients required fewer shocks, but there was no difference in survival to discharge.2 Furthermore, one study showed that amiodarone or lidocaine administered intravenously, but not intraosseously, was associated with significantly improved survival to discharge compared to placebo.4 Many of the observational studies lacked a control population, complicating their interpretation. Many of these studies compared antiarrhythmics to one another (lidocaine versus amiodarone, nifekalant versus amiodarone); the majority found no difference in survival to discharge between different antiarrhythmics. Interestingly, in a study of adults with non-traumatic cardiac arrest, Huang et al. found that survival to ICU admission, survival to discharge, and 1-year survival were highest when patients with refractory shockable rhythms were given both lidocaine and amiodarone.12 Survival to discharge was less likely in those only administered amiodarone, lower still in those only administered lidocaine, and lowest in those receiving neither. Ji et al. demonstrated higher ROSC and 24 hour survival, decreased number of shocks, lower defibrillation energy, epinephrine dose, and duration of CPR in pigs with refractory shockable rhythms administered amiodarone or nifekalant when compared to saline.13 Similarly, Zoerner et al. found greater 3-hour survival in pigs administered amiodarone in a hemorrhagic shock VF model.16 However, Karlis et al. found higher survival with nifekalant compared to amiodarone and saline and no difference in 48 hour survival between the control and amiodarone groups.15 Similarly, Glover et al. found no difference in survival between amiodarone and placebo. 14

Paragraph 145 0
No paragraph-level conversations.
Paragraph 145, Sentence 1 0
No sentence-level conversations.
Paragraph 145, Sentence 2 0
No sentence-level conversations.
Paragraph 145, Sentence 3 0
No sentence-level conversations.
Paragraph 145, Sentence 4 0
No sentence-level conversations.
Paragraph 145, Sentence 5 0
No sentence-level conversations.
Paragraph 145, Sentence 6 0
No sentence-level conversations.

146 Outcome 3: ROSC

Paragraph 146 0
No paragraph-level conversations.
Paragraph 146, Sentence 1 0
No sentence-level conversations.

147 For the next most important outcome of ROSC, we evaluated 1 clinical trial (low quality of evidence, downgraded for serious indirectness), 2 observational studies (very low quality of evidence, downgraded for serious indirectness) and 7 experimental studies (very low quality of evidence, downgraded for serious indirectness, serious imprecision, and serious inconsistency), 3 in dogs and 4 in swine. The clinical trial and 2 observational studies showed no difference in frequency of ROSC with the use of amiodarone in patients with refractory shockable rhythms.2,7,8 The experimental studies had heterogenous study designs, but overall 1 of 4 swine studies and 2 of 3 canine studies showed improvement in the frequency of ROSC in animals receiving amiodarone.13,17,18 The remainder of the studies showed no difference in ROSC between the amiodarone and control groups.15,16,19,20

Paragraph 147 0
No paragraph-level conversations.
Paragraph 147, Sentence 1 0
No sentence-level conversations.
Paragraph 147, Sentence 2 0
No sentence-level conversations.

148 Outcome 4: Surrogate markers of perfusion

Paragraph 148 0
No paragraph-level conversations.
Paragraph 148, Sentence 1 0
No sentence-level conversations.

149 For the outcome of surrogate markers of perfusion, 9 experimental studies were identified (very low quality of evidence, downgraded for serious indirectness, imprecision, and inconsistency). It is important to note that multiple experimental studies demonstrated lower coronary perfusion pressure in dogs and pigs administered amiodarone in the absence of concurrent vasopressor therapy13,18,19 The vasodilatory effects of amiodarone may be reduced when epinephrine is administered concurrently with amiodarone.17 It should also be noted that IV amiodarone does not appear to increase the defibrillation threshold, unlike oral amiodarone.21,22 Of the 9 studies, 4 were in dogs. Two showed improvement in surrogate markers of perfusion in dogs with refractory shockable rhythms with the addition of amiodarone, 1 showed no difference, and 1 showed worsened surrogate markers of perfusion.17–19,23

Paragraph 149 0
No paragraph-level conversations.
Paragraph 149, Sentence 1 0
No sentence-level conversations.
Paragraph 149, Sentence 2 0
No sentence-level conversations.
Paragraph 149, Sentence 3 0
No sentence-level conversations.

150 Treatment recommendation

Paragraph 150 0
No paragraph-level conversations.
Paragraph 150, Sentence 1 0
No sentence-level conversations.

151 If lidocaine is unavailable, we suggest that amiodarone may be administered intravenously (5 mg/kg) during CPR for PVT or VF refractory to the first shock in dogs (weak recommendation, very low quality of evidence).

Paragraph 151 0
No paragraph-level conversations.
Paragraph 151, Sentence 1 0
No sentence-level conversations.

152 We suggest that amiodarone may be administered intravenously (5 mg/kg) during CPR for PVT or VF refractory to the first shock in cats (weak recommendation, very low quality of evidence).

Paragraph 152 0
No paragraph-level conversations.
Paragraph 152, Sentence 1 0
No sentence-level conversations.

153 We recommend against the use of amiodarone formulations containing polysorbate-80 in dogs due to the adverse hemodynamic side effects of these formulations that have been documented (strong recommendation, moderate quality of evidence).

Paragraph 153 0
No paragraph-level conversations.
Paragraph 153, Sentence 1 0
No sentence-level conversations.

154 Justification of treatment recommendation

Paragraph 154 0
No paragraph-level conversations.
Paragraph 154, Sentence 1 0
No sentence-level conversations.

155 Clinical trials and observational studies in people and experimental studies in pigs and dogs found conflicting results for the efficacy of amiodarone for the treatment of refractory PVT and VF. Many of the observational studies lacked a placebo group (instead comparing lidocaine to amiodarone therapy), complicating their interpretation. There is very little evidence suggesting that amiodarone is superior to lidocaine in these studies. The evidence of profound adverse hemodynamic effects in dogs of amiodarone formulations containing polysorbate-80 indicates that these formulations should not be used during CPR in dogs.24 The alternative aqueous formulations of amiodarone are reportedly safer25, but they are pre-diluted to a low concentration, requiring infusion of large volumes (approximately 3.3 ml/kg) to achieve the recommended dose, which may be impractical during CPR. There is one case report of successful treatment of VT in a cat using the aqueous formulation of amiodarone.26 For these reasons, the committee suggests that amiodarone can be used for dogs and cats with PVT or VF refractory to an initial attempt at defibrillation, but if lidocaine is available, it is the more practical and safer drug in dogs.

Paragraph 155 0
No paragraph-level conversations.
Paragraph 155, Sentence 1 0
No sentence-level conversations.
Paragraph 155, Sentence 2 0
No sentence-level conversations.
Paragraph 155, Sentence 3 0
No sentence-level conversations.
Paragraph 155, Sentence 4 0
No sentence-level conversations.
Paragraph 155, Sentence 5 0
No sentence-level conversations.

156 Knowledge gaps

Paragraph 156 0
No paragraph-level conversations.
Paragraph 156, Sentence 1 0
No sentence-level conversations.

157 There are no controlled studies evaluating amiodarone administration in dogs and cats with spontaneous CPA and amiodarone has not been evaluated in cats. The optimal timing and dosage for amiodarone administration during CPR is unknown. Additionally, whether amiodarone should be administered concurrently with lidocaine to improve outcomes is unknown. Compared to human medicine, shockable rhythms in veterinary medicine appear less common.[ Hohene, in press] Therefore, the role of amiodarone for management of refractory pVT or VF is considered a low-priority knowledge gap in the veterinary literature.

Paragraph 157 0
No paragraph-level conversations.
Paragraph 157, Sentence 1 0
No sentence-level conversations.
Paragraph 157, Sentence 2 0
No sentence-level conversations.
Paragraph 157, Sentence 3 0
No sentence-level conversations.
Paragraph 157, Sentence 4 0
No sentence-level conversations.
Paragraph 157, Sentence 5 0
No sentence-level conversations.

158 References:

Paragraph 158 0
No paragraph-level conversations.
Paragraph 158, Sentence 1 0
No sentence-level conversations.

159 1. Fletcher DJ, Boller M, Brainard BM, et al. RECOVER evidence and knowledge gap analysis on veterinary CPR. Part 7: Clinical guidelines: RECOVER clinical guidelines. J Vet Emerg Crit Care. 2012;22(s1):S102-S131.

Paragraph 159 0
No paragraph-level conversations.
Paragraph 159, Sentence 1 0
No sentence-level conversations.
Paragraph 159, Sentence 2 0
No sentence-level conversations.
Paragraph 159, Sentence 3 0
No sentence-level conversations.
Paragraph 159, Sentence 4 0
No sentence-level conversations.
Paragraph 159, Sentence 5 0
No sentence-level conversations.
Paragraph 159, Sentence 6 0
No sentence-level conversations.

160 2. Kudenchuk PJ, Leroux BG, Daya M, et al. Antiarrhythmic Drugs for Nonshockable-Turned-Shockable Out-of-Hospital Cardiac Arrest: The ALPS Study (Amiodarone, Lidocaine, or Placebo). Circulation. 2017;136(22):2119-2131.

Paragraph 160 0
No paragraph-level conversations.
Paragraph 160, Sentence 1 0
No sentence-level conversations.
Paragraph 160, Sentence 2 0
No sentence-level conversations.
Paragraph 160, Sentence 3 0
No sentence-level conversations.
Paragraph 160, Sentence 4 0
No sentence-level conversations.
Paragraph 160, Sentence 5 0
No sentence-level conversations.

161 3. Kudenchuk PJ, Brown SP, Daya M, et al. Amiodarone, Lidocaine, or Placebo in Out-of-Hospital Cardiac Arrest. N Engl J Med. 2016;374(18):1711-1722.

Paragraph 161 0
No paragraph-level conversations.
Paragraph 161, Sentence 1 0
No sentence-level conversations.
Paragraph 161, Sentence 2 0
No sentence-level conversations.
Paragraph 161, Sentence 3 0
No sentence-level conversations.
Paragraph 161, Sentence 4 0
No sentence-level conversations.
Paragraph 161, Sentence 5 0
No sentence-level conversations.

162 4. Daya MR, Leroux BG, Dorian P, et al. Survival After Intravenous Versus Intraosseous Amiodarone, Lidocaine, or Placebo in Out-of-Hospital Shock-Refractory Cardiac Arrest. Circulation. 2020;141(3):188-198.

Paragraph 162 0
No paragraph-level conversations.
Paragraph 162, Sentence 1 0
No sentence-level conversations.
Paragraph 162, Sentence 2 0
No sentence-level conversations.
Paragraph 162, Sentence 3 0
No sentence-level conversations.
Paragraph 162, Sentence 4 0
No sentence-level conversations.
Paragraph 162, Sentence 5 0
No sentence-level conversations.

163 5. Holmberg MJ, Ross CE, Atkins DL, et al. Lidocaine versus amiodarone for pediatric in-hospital cardiac arrest: An observational study. Resuscitation. 2020;149:191-201.

Paragraph 163 0
No paragraph-level conversations.
Paragraph 163, Sentence 1 0
No sentence-level conversations.
Paragraph 163, Sentence 2 0
No sentence-level conversations.
Paragraph 163, Sentence 3 0
No sentence-level conversations.
Paragraph 163, Sentence 4 0
No sentence-level conversations.
Paragraph 163, Sentence 5 0
No sentence-level conversations.

164 6. Wang CH, Chang WT, Huang CH, et al. Outcomes associated with amiodarone and lidocaine for the treatment of adult in-hospital cardiac arrest with shock-refractory pulseless ventricular tachyarrhythmia. J Formos Med Assoc. 2020;119(1 Pt 2):327-334.

Paragraph 164 0
No paragraph-level conversations.
Paragraph 164, Sentence 1 0
No sentence-level conversations.
Paragraph 164, Sentence 2 0
No sentence-level conversations.
Paragraph 164, Sentence 3 0
No sentence-level conversations.
Paragraph 164, Sentence 4 0
No sentence-level conversations.
Paragraph 164, Sentence 5 0
No sentence-level conversations.

165 7. Valdes SO, Donoghue AJ, Hoyme DB, et al. Outcomes associated with amiodarone and lidocaine in the treatment of in-hospital pediatric cardiac arrest with pulseless ventricular tachycardia or ventricular fibrillation. Resuscitation. 2014;85(3):381-386.

Paragraph 165 0
No paragraph-level conversations.
Paragraph 165, Sentence 1 0
No sentence-level conversations.
Paragraph 165, Sentence 2 0
No sentence-level conversations.
Paragraph 165, Sentence 3 0
No sentence-level conversations.
Paragraph 165, Sentence 4 0
No sentence-level conversations.
Paragraph 165, Sentence 5 0
No sentence-level conversations.

166 8. Pollak PT, Wee V, Al-Hazmi A, Martin J, Zarnke KB. The use of amiodarone for in-hospital cardiac arrest at two tertiary care centres. Can J Cardiol. 2006;22(3):199-202.

Paragraph 166 0
No paragraph-level conversations.
Paragraph 166, Sentence 1 0
No sentence-level conversations.
Paragraph 166, Sentence 2 0
No sentence-level conversations.
Paragraph 166, Sentence 3 0
No sentence-level conversations.
Paragraph 166, Sentence 4 0
No sentence-level conversations.
Paragraph 166, Sentence 5 0
No sentence-level conversations.

167 9. Amino M, Inokuchi S, Nagao K, et al. Nifekalant Hydrochloride and Amiodarone Hydrochloride Result in Similar Improvements for 24-Hour Survival in Cardiopulmonary Arrest Patients: The SOS-KANTO 2012 Study. J Cardiovasc Pharmacol. 2015;66(6):600-609.

Paragraph 167 0
No paragraph-level conversations.
Paragraph 167, Sentence 1 0
No sentence-level conversations.
Paragraph 167, Sentence 2 0
No sentence-level conversations.
Paragraph 167, Sentence 3 0
No sentence-level conversations.
Paragraph 167, Sentence 4 0
No sentence-level conversations.
Paragraph 167, Sentence 5 0
No sentence-level conversations.

168 10. Tagami T, Matsui H, Tanaka C, et al. Amiodarone Compared with Lidocaine for Out-Of-Hospital Cardiac Arrest with Refractory Ventricular Fibrillation on Hospital Arrival: a Nationwide Database Study. Cardiovasc Drugs Ther. 2016;30(5):485-491.

Paragraph 168 0
No paragraph-level conversations.
Paragraph 168, Sentence 1 0
No sentence-level conversations.
Paragraph 168, Sentence 2 0
No sentence-level conversations.
Paragraph 168, Sentence 3 0
No sentence-level conversations.
Paragraph 168, Sentence 4 0
No sentence-level conversations.
Paragraph 168, Sentence 5 0
No sentence-level conversations.

169 11. Tagami T, Matsui H, Ishinokami S, et al. Amiodarone or nifekalant upon hospital arrival for refractory ventricular fibrillation after out-of-hospital cardiac arrest. Resuscitation. 2016;109:127-132.

Paragraph 169 0
No paragraph-level conversations.
Paragraph 169, Sentence 1 0
No sentence-level conversations.
Paragraph 169, Sentence 2 0
No sentence-level conversations.
Paragraph 169, Sentence 3 0
No sentence-level conversations.
Paragraph 169, Sentence 4 0
No sentence-level conversations.
Paragraph 169, Sentence 5 0
No sentence-level conversations.

170 12. Huang CH, Yu PH, Tsai MS, et al. Acute hospital administration of amiodarone and/or lidocaine in shockable patients presenting with out-of-hospital cardiac arrest: A nationwide cohort study. Int J Cardiol. 2017;227:292-298.

Paragraph 170 0
No paragraph-level conversations.
Paragraph 170, Sentence 1 0
No sentence-level conversations.
Paragraph 170, Sentence 2 0
No sentence-level conversations.
Paragraph 170, Sentence 3 0
No sentence-level conversations.
Paragraph 170, Sentence 4 0
No sentence-level conversations.
Paragraph 170, Sentence 5 0
No sentence-level conversations.

171 13. Ji XF, Li CS, Wang S, Yang L, Cong LH. Comparison of the efficacy of nifekalant and amiodarone in a porcine model of cardiac arrest. Resuscitation. 2010;81(8):1031-1036.

Paragraph 171 0
No paragraph-level conversations.
Paragraph 171, Sentence 1 0
No sentence-level conversations.
Paragraph 171, Sentence 2 0
No sentence-level conversations.
Paragraph 171, Sentence 3 0
No sentence-level conversations.
Paragraph 171, Sentence 4 0
No sentence-level conversations.
Paragraph 171, Sentence 5 0
No sentence-level conversations.

172 14. Glover BM, Hu X, Aves T, et al. Dronedarone and captisol-enabled amiodarone in an experimental cardiac arrest. J Cardiovasc Pharmacol. 2013;61(5):385-390.

Paragraph 172 0
No paragraph-level conversations.
Paragraph 172, Sentence 1 0
No sentence-level conversations.
Paragraph 172, Sentence 2 0
No sentence-level conversations.
Paragraph 172, Sentence 3 0
No sentence-level conversations.
Paragraph 172, Sentence 4 0
No sentence-level conversations.
Paragraph 172, Sentence 5 0
No sentence-level conversations.

173 15. Karlis G, Iacovidou N, Lelovas P, et al. Nifekalant Versus Amiodarone in the Treatment of Cardiac Arrest: an Experimental Study in a Swine Model of Prolonged Ventricular Fibrillation. Cardiovasc Drugs Ther. 2015;29(5):425-431.

Paragraph 173 0
No paragraph-level conversations.
Paragraph 173, Sentence 1 0
No sentence-level conversations.
Paragraph 173, Sentence 2 0
No sentence-level conversations.
Paragraph 173, Sentence 3 0
No sentence-level conversations.
Paragraph 173, Sentence 4 0
No sentence-level conversations.
Paragraph 173, Sentence 5 0
No sentence-level conversations.

174 16. Zoerner F, Semenas E. Resuscitation with amiodarone increases survival after hemorrhage and ventricular fibrillation in pigs. J Trauma Acute Care Surg. 2014;76(6):1402-1408.

Paragraph 174 0
No paragraph-level conversations.
Paragraph 174, Sentence 1 0
No sentence-level conversations.
Paragraph 174, Sentence 2 0
No sentence-level conversations.
Paragraph 174, Sentence 3 0
No sentence-level conversations.
Paragraph 174, Sentence 4 0
No sentence-level conversations.

175 17. Wira C, Martin G, Stoner J, Margolis K, Donnino M. Application of normothermic cardiac arrest algorithms to hypothermic cardiac arrest in a canine model. Resuscitation. 2006;69(3):509-516.

Paragraph 175 0
No paragraph-level conversations.
Paragraph 175, Sentence 1 0
No sentence-level conversations.
Paragraph 175, Sentence 2 0
No sentence-level conversations.
Paragraph 175, Sentence 3 0
No sentence-level conversations.
Paragraph 175, Sentence 4 0
No sentence-level conversations.

176 18. Anastasiou-Nana MI, Nanas JN, Nanas SN, et al. Effects of amiodarone on refractory ventricular fibrillation in acute myocardial infarction: experimental study. J Am Coll Cardiol. 1994;23(1):253-258.

Paragraph 176 0
No paragraph-level conversations.
Paragraph 176, Sentence 1 0
No sentence-level conversations.
Paragraph 176, Sentence 2 0
No sentence-level conversations.
Paragraph 176, Sentence 3 0
No sentence-level conversations.
Paragraph 176, Sentence 4 0
No sentence-level conversations.
Paragraph 176, Sentence 5 0
No sentence-level conversations.

177 19. Stoner J, Martin G, O’Mara K, Ehlers J, Tomlanovich M. Amiodarone and bretylium in the treatment of hypothermic ventricular fibrillation in a canine model. Acad Emerg Med. 2003;10(3):187-191.

Paragraph 177 0
No paragraph-level conversations.
Paragraph 177, Sentence 1 0
No sentence-level conversations.
Paragraph 177, Sentence 2 0
No sentence-level conversations.
Paragraph 177, Sentence 3 0
No sentence-level conversations.
Paragraph 177, Sentence 4 0
No sentence-level conversations.

178 20. Wiesmann T, Freitag D, Dersch W, et al. Dantrolene versus amiodarone for cardiopulmonary resuscitation: A randomized, double-blinded experimental study. Sci Rep. 2017;7.

Paragraph 178 0
No paragraph-level conversations.
Paragraph 178, Sentence 1 0
No sentence-level conversations.
Paragraph 178, Sentence 2 0
No sentence-level conversations.
Paragraph 178, Sentence 3 0
No sentence-level conversations.
Paragraph 178, Sentence 4 0
No sentence-level conversations.
Paragraph 178, Sentence 5 0
No sentence-level conversations.

179 21. FRAME LH. The Effect of Chronic Oral and Acute Intravenous Amiodarone Administration on Ventricular Defibrillation Threshold Using Implanted Electrodes in Dogs. Pacing Clin Electrophysiol. 1989;12(2):339-346.

Paragraph 179 0
No paragraph-level conversations.
Paragraph 179, Sentence 1 0
No sentence-level conversations.
Paragraph 179, Sentence 2 0
No sentence-level conversations.
Paragraph 179, Sentence 3 0
No sentence-level conversations.
Paragraph 179, Sentence 4 0
No sentence-level conversations.
Paragraph 179, Sentence 5 0
No sentence-level conversations.

180 22. Fain ES, Lee JT, Winkle RA. Effects of acute intravenous and chronic oral amiodarone on defibrillation energy requirements. Am Heart J. 1987;114(1 PART 1):8-17.

Paragraph 180 0
No paragraph-level conversations.
Paragraph 180, Sentence 1 0
No sentence-level conversations.
Paragraph 180, Sentence 2 0
No sentence-level conversations.
Paragraph 180, Sentence 3 0
No sentence-level conversations.
Paragraph 180, Sentence 4 0
No sentence-level conversations.
Paragraph 180, Sentence 5 0
No sentence-level conversations.

181 23. Arredondo MT, Guillen SG, Quinteiro RA. Effect of amiodarone on ventricular fibrillation and defibrillation thresholds in the canine heart under normal and ischemic conditions. Eur J Pharmacol. 1986;125(1):23-28.

Paragraph 181 0
No paragraph-level conversations.
Paragraph 181, Sentence 1 0
No sentence-level conversations.
Paragraph 181, Sentence 2 0
No sentence-level conversations.
Paragraph 181, Sentence 3 0
No sentence-level conversations.
Paragraph 181, Sentence 4 0
No sentence-level conversations.
Paragraph 181, Sentence 5 0
No sentence-level conversations.

182 24. Masini E, Planchenault J, Pezziardi F, Gautier P, Gagnol JP. Histamine-releasing properties of Polysorbate 80 in vitro and in vivo: correlation with its hypotensive action in the dog. Agents Actions. 1985;16(6):470-477.

Paragraph 182 0
No paragraph-level conversations.
Paragraph 182, Sentence 1 0
No sentence-level conversations.
Paragraph 182, Sentence 2 0
No sentence-level conversations.
Paragraph 182, Sentence 3 0
No sentence-level conversations.
Paragraph 182, Sentence 4 0
No sentence-level conversations.
Paragraph 182, Sentence 5 0
No sentence-level conversations.

183 25. Levy NA, Koenigshof AM, Sanders RA. Retrospective evaluation of intravenous premixed amiodarone use and adverse effects in dogs (17 cases: 2011-2014). J Vet Cardiol Off J Eur Soc Vet Cardiol. 2016;18(1):10-14.

Paragraph 183 0
No paragraph-level conversations.
Paragraph 183, Sentence 1 0
No sentence-level conversations.
Paragraph 183, Sentence 2 0
No sentence-level conversations.
Paragraph 183, Sentence 3 0
No sentence-level conversations.
Paragraph 183, Sentence 4 0
No sentence-level conversations.
Paragraph 183, Sentence 5 0
No sentence-level conversations.

184 26. Berlin N, Ohad DG, Maiorkis I, Kelmer E. Successful management of ventricular fibrillation and ventricular tachycardia using defibrillation and intravenous amiodarone therapy in a cat. J Vet Emerg Crit Care San Antonio. Published online 2020.

Paragraph 184 0
No paragraph-level conversations.
Paragraph 184, Sentence 1 0
No sentence-level conversations.
Paragraph 184, Sentence 2 0
No sentence-level conversations.
Paragraph 184, Sentence 3 0
No sentence-level conversations.
Paragraph 184, Sentence 4 0
No sentence-level conversations.

185 Additional References:

Paragraph 185 0
No paragraph-level conversations.
Paragraph 185, Sentence 1 0
No sentence-level conversations.

186 Masini E, Planchenault J, Pezziardi F, Gautier P, Gagnol JP. Histamine-releasing properties of Polysorbate 80 in vitro and in vivo: correlation with its hypotensive action in the dog. Agents Actions. 1985; 16: 470–477.

Paragraph 186 0
No paragraph-level conversations.
Paragraph 186, Sentence 1 0
No sentence-level conversations.
Paragraph 186, Sentence 2 0
No sentence-level conversations.
Paragraph 186, Sentence 3 0
No sentence-level conversations.
Paragraph 186, Sentence 4 0
No sentence-level conversations.

187 Levy NA, Koenigshof AM, Sanders RA. Retrospective evaluation of intravenous premixed amiodarone use and adverse effects in dogs (17 cases: 2011-2014). J Vet Cardiol. 2016 Mar;18(1):10-4. doi: 10.1016/j.jvc.2015.10.009. Epub 2016 Jan 21. PMID: 26803199.

Paragraph 187 0
No paragraph-level conversations.
Paragraph 187, Sentence 1 0
No sentence-level conversations.
Paragraph 187, Sentence 2 0
No sentence-level conversations.
Paragraph 187, Sentence 3 0
No sentence-level conversations.
Paragraph 187, Sentence 4 0
No sentence-level conversations.
Paragraph 187, Sentence 5 0
No sentence-level conversations.
Paragraph 187, Sentence 6 0
No sentence-level conversations.

188 Berlin N, Ohad DG, Maiorkis I, Kelmer E. Successful management of ventricular fibrillation and ventricular tachycardia using defibrillation and intravenous amiodarone therapy in a cat. J Vet Emerg Crit Care (San Antonio). 2020 Jul;30(4):474-480. doi: 10.1111/vec.12960. Epub 2020 May 13. PMID: 32400960

Paragraph 188 0
No paragraph-level conversations.
Paragraph 188, Sentence 1 0
No sentence-level conversations.
Paragraph 188, Sentence 2 0
No sentence-level conversations.
Paragraph 188, Sentence 3 0
No sentence-level conversations.
Paragraph 188, Sentence 4 0
No sentence-level conversations.
Paragraph 188, Sentence 5 0
No sentence-level conversations.

189 Supplemental Information:

Paragraph 189 0
No paragraph-level conversations.
Paragraph 189, Sentence 1 0
No sentence-level conversations.

190 Outcome: Favorable neurologic outcome

Paragraph 190 0
No paragraph-level conversations.
Paragraph 190, Sentence 1 0
No sentence-level conversations.

191 3 Clinical Trials

Paragraph 191 0
No paragraph-level conversations.
Paragraph 191, Sentence 1 0
No sentence-level conversations.

192 Kudenchuk et al., 2016: Amiodarone, lidocaine, or placebo in OOHCA

Paragraph 192 0
No paragraph-level conversations.
Paragraph 192, Sentence 1 0
No sentence-level conversations.

193 Randomized, double blind trial of adults with non-traumatic OOHCA and shock refractory VF or PVT (shock refractory: persistent or recurrent shockable rhythm after one or more shocks anytime during resuscitation)

Paragraph 193 0
No paragraph-level conversations.
Paragraph 193, Sentence 1 0
No sentence-level conversations.

194 Patients then randomized to receive amiodarone, lidocaine, or placebo after a vasopressor

Paragraph 194 0
No paragraph-level conversations.
Paragraph 194, Sentence 1 0
No sentence-level conversations.

195 Neither amiodarone nor lidocaine resulted in a higher survivor or favorable neuro outcome than placebo

Paragraph 195 0
No paragraph-level conversations.
Paragraph 195, Sentence 1 0
No sentence-level conversations.

196 With witnessed arrest, lidocaine and amiodarone had significantly higher survival than placebo

Paragraph 196 0
No paragraph-level conversations.
Paragraph 196, Sentence 1 0
No sentence-level conversations.

197 Kudenchuk et al., 2017: Antiarrhythmic drugs for nonshockable turned shockable OOHCA

Paragraph 197 0
No paragraph-level conversations.
Paragraph 197, Sentence 1 0
No sentence-level conversations.

198 Adults with nontraumatic OOHCA and VF/PVT anytime after one or more shocks randomized to placebo, lidocaine, or amiodarone

Paragraph 198 0
No paragraph-level conversations.
Paragraph 198, Sentence 1 0
No sentence-level conversations.

199 3026 with VF/PVT and 1063 with nonshockable turned shockable

Paragraph 199 0
No paragraph-level conversations.
Paragraph 199, Sentence 1 0
No sentence-level conversations.

200 Non-statistically significant increase in survival (and improved neuro outcome) with amiodarone or lidocaine compared to placebo

Paragraph 200 0
No paragraph-level conversations.
Paragraph 200, Sentence 1 0
No sentence-level conversations.

201 Active-drug recipients in this cohort required fewer shocks, supplemental doses of their assigned drug, and ancillary antiarrhythmic drugs than recipients of a placebo

Paragraph 201 0
No paragraph-level conversations.
Paragraph 201, Sentence 1 0
No sentence-level conversations.

202 Survival approached significance (p 0.08) for nonshockable turned shockable rhythms with amiodarone compared to placebo

Paragraph 202 0
No paragraph-level conversations.
Paragraph 202, Sentence 1 0
No sentence-level conversations.

203 Daye et al., 2020: Survival after IV versus IO amiodarone, lidocaine, or placebo in OOH shock-refractory cardiac arrest

Paragraph 203 0
No paragraph-level conversations.
Paragraph 203, Sentence 1 0
No sentence-level conversations.

204 Same study population as previous study

Paragraph 204 0
No paragraph-level conversations.
Paragraph 204, Sentence 1 0
No sentence-level conversations.

205 Amiodarone and lidocaine associated with more favorable neuro outcome when administered IV, but not IO when compared to placebo (as was survival to discharge and survival to hospital admission)

Paragraph 205 0
No paragraph-level conversations.
Paragraph 205, Sentence 1 0
No sentence-level conversations.

206 2 Observational Studies

Paragraph 206 0
No paragraph-level conversations.
Paragraph 206, Sentence 1 0
No sentence-level conversations.

207 Holmberg et al., 2020: Lidocaine versus amiodarone for pediatric in hospital cardiac arrest: an observational study

Paragraph 207 0
No paragraph-level conversations.
Paragraph 207, Sentence 1 0
No sentence-level conversations.

208 From registry, included children with IHCA with an initial or subsequent shockable rhythm and then matched based on a propensity score

Paragraph 208 0
No paragraph-level conversations.
Paragraph 208, Sentence 1 0
No sentence-level conversations.

209 No difference between lidocaine and amiodarone for survival, ROSC, or favorable neuro outcome

Paragraph 209 0
No paragraph-level conversations.
Paragraph 209, Sentence 1 0
No sentence-level conversations.

210 Wang et al., 2020: Outcomes associated with amiodarone and lidocaine for the treatment for adult IHCA with shock refractory pulseless ventricular tachyarrhythmia

Paragraph 210 0
No paragraph-level conversations.
Paragraph 210, Sentence 1 0
No sentence-level conversations.

211 Included 130 patients with IHCA and VF/pVT requiring more than one defibrillation attempt

Paragraph 211 0
No paragraph-level conversations.
Paragraph 211, Sentence 1 0
No sentence-level conversations.

212 No control group. No difference in ROSC, survival or favorable neuro outcome for lidocaine v amiodarone. Amiodarone group experienced a higher likelihood of terminating VF/pVT within three shocks

Paragraph 212 0
No paragraph-level conversations.
Paragraph 212, Sentence 1 0
No sentence-level conversations.
Paragraph 212, Sentence 2 0
No sentence-level conversations.
Paragraph 212, Sentence 3 0
No sentence-level conversations.

213 0 Experimental Studies

Paragraph 213 0
No paragraph-level conversations.
Paragraph 213, Sentence 1 0
No sentence-level conversations.

214 Outcome: Survival to discharge

Paragraph 214 0
No paragraph-level conversations.
Paragraph 214, Sentence 1 0
No sentence-level conversations.

215 3 Clinical Trials

Paragraph 215 0
No paragraph-level conversations.
Paragraph 215, Sentence 1 0
No sentence-level conversations.

216 Kudenchuk et al., 2016: Amiodarone, lidocaine, or placebo in OOHCA

Paragraph 216 0
No paragraph-level conversations.
Paragraph 216, Sentence 1 0
No sentence-level conversations.

217 Randomized, double blind trial of adults with non-traumatic OOHCA and shock refractory VF or PVT (shock refractory: persistent or recurrent shockable rhythm after one or more shocks anytime during resuscitation). Patients then randomized to receive amiodarone, lidocaine, or placebo after a vasopressor

Paragraph 217 0
No paragraph-level conversations.
Paragraph 217, Sentence 1 0
No sentence-level conversations.
Paragraph 217, Sentence 2 0
No sentence-level conversations.

218 Neither amiodarone nor lidocaine resulted in a higher survivor or favorable neuro outcome than placebo

Paragraph 218 0
No paragraph-level conversations.
Paragraph 218, Sentence 1 0
No sentence-level conversations.

219 With witnessed arrest, lidocaine and amiodarone had significantly higher survival than placebo

Paragraph 219 0
No paragraph-level conversations.
Paragraph 219, Sentence 1 0
No sentence-level conversations.

220 Kudenchuk et al., 2017: Antiarrhythmic drugs for nonshockable turned shockable OOHCA

Paragraph 220 0
No paragraph-level conversations.
Paragraph 220, Sentence 1 0
No sentence-level conversations.

221 Adults with nontraumatic OOHCA and VF/PVT anytime after one or more shocks randomized to placebo, lidocaine, or amiodarone

Paragraph 221 0
No paragraph-level conversations.
Paragraph 221, Sentence 1 0
No sentence-level conversations.

222 3026 with VF/PVT and 1063 with nonshockable turned shockable

Paragraph 222 0
No paragraph-level conversations.
Paragraph 222, Sentence 1 0
No sentence-level conversations.

223 Non-statistically significant increase in survival (and improved neuro outcome) with amiodarone or lidocaine compared to placebo

Paragraph 223 0
No paragraph-level conversations.
Paragraph 223, Sentence 1 0
No sentence-level conversations.

224 Survival approached significance (p 0.08) for nonshockable turned shockable rhythms with amiodarone compared to placebo

Paragraph 224 0
No paragraph-level conversations.
Paragraph 224, Sentence 1 0
No sentence-level conversations.

225 Daye et al., 2020: Survival after IV versus IO amiodarone, lidocaine, or placebo in OOH shock-refractory cardiac arrest

Paragraph 225 0
No paragraph-level conversations.
Paragraph 225, Sentence 1 0
No sentence-level conversations.

226 Same study population as previous study

Paragraph 226 0
No paragraph-level conversations.
Paragraph 226, Sentence 1 0
No sentence-level conversations.

227 Amiodarone and lidocaine associated with more survival to discharge and survival to hospital admission when administered IV, but not IO when compared to placebo

Paragraph 227 0
No paragraph-level conversations.
Paragraph 227, Sentence 1 0
No sentence-level conversations.

228 8 Observational Studies

Paragraph 228 0
No paragraph-level conversations.
Paragraph 228, Sentence 1 0
No sentence-level conversations.

229 Valdes et al., 2014: Outcomes associated with amiodarone and lidocaine in the treatment of in hospital pediatric cardiac arrest with pVT or VF

Paragraph 229 0
No paragraph-level conversations.
Paragraph 229, Sentence 1 0
No sentence-level conversations.

230 Retrospective cohort study for inpatient cardiac arrest in 889 patients

Paragraph 230 0
No paragraph-level conversations.
Paragraph 230, Sentence 1 0
No sentence-level conversations.

231 Lidocaine associated with improved ROSC and 24 hour survival but not hospital discharge. Amiodarone not associated with ROSC or survival

Paragraph 231 0
No paragraph-level conversations.
Paragraph 231, Sentence 1 0
No sentence-level conversations.
Paragraph 231, Sentence 2 0
No sentence-level conversations.

232 Pollak et al., 2006: The use of amiodarone for in hospital cardiac arrest at two tertiary care centres

Paragraph 232 0
No paragraph-level conversations.
Paragraph 232, Sentence 1 0
No sentence-level conversations.

233 374 charts retrospectively examined; shockable rhythms present in 95 patients

Paragraph 233 0
No paragraph-level conversations.
Paragraph 233, Sentence 1 0
No sentence-level conversations.

234 No difference in ROSC or survival between amiodarone and patients receiving only other antiarrhythmics (though amiodarone trended towards lower ROSC and survival)

Paragraph 234 0
No paragraph-level conversations.
Paragraph 234, Sentence 1 0
No sentence-level conversations.

235 Holmberg et al., 2020: Lidocaine versus amiodarone for pediatric in hospital cardiac arrest: an observational study

Paragraph 235 0
No paragraph-level conversations.
Paragraph 235, Sentence 1 0
No sentence-level conversations.

236 From registry, included children with IHCA with an initial or subsequent shockable rhythm and then matched based on a propensity score

Paragraph 236 0
No paragraph-level conversations.
Paragraph 236, Sentence 1 0
No sentence-level conversations.

237 No difference between lidocaine and amiodarone for survival, ROSC, or favorable neuro outcome

Paragraph 237 0
No paragraph-level conversations.
Paragraph 237, Sentence 1 0
No sentence-level conversations.

238 Wang et al., 2020: Outcomes associated with amiodarone and lidocaine for the treatment for adult IHCA with shock refractory pulseless ventricular tachyarrhythmia

Paragraph 238 0
No paragraph-level conversations.
Paragraph 238, Sentence 1 0
No sentence-level conversations.

239 Included 130 patients with IHCA and VF/pVT requiring more than one defibrillation attempt

Paragraph 239 0
No paragraph-level conversations.
Paragraph 239, Sentence 1 0
No sentence-level conversations.

240 No control group. No difference in ROSC, survival or favorable neuro outcome for lidocaine v amiodarone.

Paragraph 240 0
No paragraph-level conversations.
Paragraph 240, Sentence 1 0
No sentence-level conversations.
Paragraph 240, Sentence 2 0
No sentence-level conversations.

241 Amino et al., 2015: Nifekalant hydrochloride and amiodarone hydrochloride result in similar improvements for 24 hours survival in CPA patients: the SOS-KANTO 2012 study

Paragraph 241 0
No paragraph-level conversations.
Paragraph 241, Sentence 1 0
No sentence-level conversations.

242 Enrolled 500 adults with OOHCA who used a single antiarrhythmic for shock resistant VF/VT. Survival to admission significantly higher with amiodarone and nifekalant compared to lidocaine and 24 hour survival. ROSC not different between groups

Paragraph 242 0
No paragraph-level conversations.
Paragraph 242, Sentence 1 0
No sentence-level conversations.
Paragraph 242, Sentence 2 0
No sentence-level conversations.
Paragraph 242, Sentence 3 0
No sentence-level conversations.

243 Tagami et al., 2016: Amiodarone or nifekalant upon hospital arrival for refractory VF after OOHCA

Paragraph 243 0
No paragraph-level conversations.
Paragraph 243, Sentence 1 0
No sentence-level conversations.

244 Retrospective cohort study of adults with cardiogenic OOHCA and with VF on hospital arrival classified into amiodarone or nifekalant groups. From there, propensity matching occurred

Paragraph 244 0
No paragraph-level conversations.
Paragraph 244, Sentence 1 0
No sentence-level conversations.
Paragraph 244, Sentence 2 0
No sentence-level conversations.

245 Amiodarone significantly less likely to be admitted to hospital but no difference in in hospital mortality

Paragraph 245 0
No paragraph-level conversations.
Paragraph 245, Sentence 1 0
No sentence-level conversations.

246 Tagami et al., 2016: Amiodarone compared with lidocaine for OOHCA with refractory VF on hospital arrival: a nationwide database study

Paragraph 246 0
No paragraph-level conversations.
Paragraph 246, Sentence 1 0
No sentence-level conversations.

247 Same procedure as above but categorized into amiodarone or lidocaine groups

Paragraph 247 0
No paragraph-level conversations.
Paragraph 247, Sentence 1 0
No sentence-level conversations.

248 No difference in survival to hospital discharge

Paragraph 248 0
No paragraph-level conversations.
Paragraph 248, Sentence 1 0
No sentence-level conversations.

249 Huang et al., 2017: Acute hospital administration of amiodarone and/or lidocaine in shockable patients presenting with OOHCA: a nationwide cohort study

Paragraph 249 0
No paragraph-level conversations.
Paragraph 249, Sentence 1 0
No sentence-level conversations.

250 Repository for insurance claims in Taiwan was searched. Included all non-traumatic adults receiving shock and CPR immediately or within 6 hours of ER arrival

Paragraph 250 0
No paragraph-level conversations.
Paragraph 250, Sentence 1 0
No sentence-level conversations.
Paragraph 250, Sentence 2 0
No sentence-level conversations.

251 Better survival to ICU admission, discharge, and 1 year survival when given both lidocaine and amiodarone (over amiodarone, then lidocaine, then neither). In intergroup comparisons, no difference between patients given one or both medications

Paragraph 251 0
No paragraph-level conversations.
Paragraph 251, Sentence 1 0
No sentence-level conversations.
Paragraph 251, Sentence 2 0
No sentence-level conversations.

252 4 Experimental Studies

Paragraph 252 0
No paragraph-level conversations.
Paragraph 252, Sentence 1 0
No sentence-level conversations.

253 Ji et al., 2010: Comparison of the efficacy of nifekalant and amiodarone in a porcine model of cardiac arrest

Paragraph 253 0
No paragraph-level conversations.
Paragraph 253, Sentence 1 0
No sentence-level conversations.

254 4 minutes of untreated VF in 36 pigs randomized to amiodarone, placebo, or nifekalant. CPR initiated after drug admin and defibrillation attempted 2 minutes later

Paragraph 254 0
No paragraph-level conversations.
Paragraph 254, Sentence 1 0
No sentence-level conversations.
Paragraph 254, Sentence 2 0
No sentence-level conversations.

255 Nifekalant and amiodarone decreased number of shocks, defibrillation energy, epi dose, and duration of CPR. Higher ROSC and 24 hour survival in both groups. Improved postresuscitation myocardial dysfunction with treatment

Paragraph 255 0
No paragraph-level conversations.
Paragraph 255, Sentence 1 0
No sentence-level conversations.
Paragraph 255, Sentence 2 0
No sentence-level conversations.
Paragraph 255, Sentence 3 0
No sentence-level conversations.

256 Glover et al., 2013: Dronedarone and captisol enabled amiodarone in an experimental cardiac arrest

Paragraph 256 0
No paragraph-level conversations.
Paragraph 256, Sentence 1 0
No sentence-level conversations.

257 42 pigs had induced VF, CPR for 3 minutes and then randomized to receive placebo, amiodarone, or dronedarone, followed by defibrillation and continued CPR

Paragraph 257 0
No paragraph-level conversations.
Paragraph 257, Sentence 1 0
No sentence-level conversations.

258 No difference in survival with amiodarone admin compared to control. Worse survival with dronedarone

Paragraph 258 0
No paragraph-level conversations.
Paragraph 258, Sentence 1 0
No sentence-level conversations.
Paragraph 258, Sentence 2 0
No sentence-level conversations.

259 Karlis et al., 2015: Nifekalant versus amiodarone in the treatment of cardiac arrest: an experimental study in a swine model of prolonged VF

Paragraph 259 0
No paragraph-level conversations.
Paragraph 259, Sentence 1 0
No sentence-level conversations.

260 8 minutes of untreated VF followed by bolus of epi and either nifekalant, amiodarone, or saline in pigs. Then CPR and defibrillation after 2 minutes

Paragraph 260 0
No paragraph-level conversations.
Paragraph 260, Sentence 1 0
No sentence-level conversations.
Paragraph 260, Sentence 2 0
No sentence-level conversations.

261 Higher survival with nifekalant v amiodarone and saline. Higher SAP, DAP, and CPP with nifekalant. Number of shocks needed, time to ROSC, and epi dose higher with amiodarone. No difference in 48 hour survival between control and amiodarone

Paragraph 261 0
No paragraph-level conversations.
Paragraph 261, Sentence 1 0
No sentence-level conversations.
Paragraph 261, Sentence 2 0
No sentence-level conversations.
Paragraph 261, Sentence 3 0
No sentence-level conversations.
Paragraph 261, Sentence 4 0
No sentence-level conversations.

262 Zoerner et al., 2014: Resuscitation with amiodarone increases survival after hemorrhage and VF in pigs

Paragraph 262 0
No paragraph-level conversations.
Paragraph 262, Sentence 1 0
No sentence-level conversations.

263 18 anesthetized piglets bled 30% blood volume to MAP of 35 mmHg followed by 4 minutes of VF and 11 minutes of open chest CPR. At 4 minutes received either amiodarone or saline. Both groups received hypertonic-hyperoncotic solution and vasopressin at this time. Defibrillation attempted from 7 min of cardiac arrest

Paragraph 263 0
No paragraph-level conversations.
Paragraph 263, Sentence 1 0
No sentence-level conversations.
Paragraph 263, Sentence 2 0
No sentence-level conversations.
Paragraph 263, Sentence 3 0
No sentence-level conversations.
Paragraph 263, Sentence 4 0
No sentence-level conversations.

264 Greater 3 hour survival in amiodarone group; also had lower HR and better SAP, DAP, and MAP. Lower troponin I and higher UOP

Paragraph 264 0
No paragraph-level conversations.
Paragraph 264, Sentence 1 0
No sentence-level conversations.
Paragraph 264, Sentence 2 0
No sentence-level conversations.

265 Outcome: ROSC

Paragraph 265 0
No paragraph-level conversations.
Paragraph 265, Sentence 1 0
No sentence-level conversations.

266 1 Clinical Trial

Paragraph 266 0
No paragraph-level conversations.
Paragraph 266, Sentence 1 0
No sentence-level conversations.

267 Kudenchuk et al., 2017: Antiarrhythmic drugs for nonshockable turned shockable OOHCA

Paragraph 267 0
No paragraph-level conversations.
Paragraph 267, Sentence 1 0
No sentence-level conversations.

268 Adults with nontraumatic OOHCA and VF/PVT anytime after one or more shocks randomized to placebo, lidocaine, or amiodarone

Paragraph 268 0
No paragraph-level conversations.
Paragraph 268, Sentence 1 0
No sentence-level conversations.

269 3026 with VF/PVT and 1063 with nonshockable turned shockable

Paragraph 269 0
No paragraph-level conversations.
Paragraph 269, Sentence 1 0
No sentence-level conversations.

270 No difference in ROSC

Paragraph 270 0
No paragraph-level conversations.
Paragraph 270, Sentence 1 0
No sentence-level conversations.

271 2 Observational Studies

Paragraph 271 0
No paragraph-level conversations.
Paragraph 271, Sentence 1 0
No sentence-level conversations.

272 Valdes et al., 2014: Outcomes associated with amiodarone and lidocaine in the treatment of in hospital pediatric cardiac arrest with pVT or VF

Paragraph 272 0
No paragraph-level conversations.
Paragraph 272, Sentence 1 0
No sentence-level conversations.

273 Retrospective cohort study for inpatient cardiac arrest in 889 patients

Paragraph 273 0
No paragraph-level conversations.
Paragraph 273, Sentence 1 0
No sentence-level conversations.

274 Lidocaine associated with improved ROSC and 24 hour survival but not hospital discharge. Amiodarone not associated with ROSC or survival

Paragraph 274 0
No paragraph-level conversations.
Paragraph 274, Sentence 1 0
No sentence-level conversations.
Paragraph 274, Sentence 2 0
No sentence-level conversations.

275 Pollak et al., 2006: The use of amiodarone for in hospital cardiac arrest at two tertiary care centres

Paragraph 275 0
No paragraph-level conversations.
Paragraph 275, Sentence 1 0
No sentence-level conversations.

276 374 charts retrospectively examined; shockable rhythms present in 95 patients

Paragraph 276 0
No paragraph-level conversations.
Paragraph 276, Sentence 1 0
No sentence-level conversations.

277 No difference in ROSC or survival between amiodarone and patients receiving only other antiarrhythmics (though amiodarone trended towards lower ROSC and survival)

Paragraph 277 0
No paragraph-level conversations.
Paragraph 277, Sentence 1 0
No sentence-level conversations.

278 Salcido et al., 2018: Effects of intra-resuscitation antiarrhythmic administration on rearrest occurrence and intra-resuscitation ECG characteristics in the ROC ALPS trial

Paragraph 278 0
No paragraph-level conversations.
Paragraph 278, Sentence 1 0
No sentence-level conversations.

279 Secondary analysis of the ALPS trial listed above

Paragraph 279 0
No paragraph-level conversations.
Paragraph 279, Sentence 1 0
No sentence-level conversations.

280 ALPS treatment group (placebo, lidocaine, or amiodarone) was not associated with rearrest

Paragraph 280 0
No paragraph-level conversations.
Paragraph 280, Sentence 1 0
No sentence-level conversations.

281 Holmberg et al., 2020: Lidocaine versus amiodarone for pediatric in hospital cardiac arrest: an observational study

Paragraph 281 0
No paragraph-level conversations.
Paragraph 281, Sentence 1 0
No sentence-level conversations.

282 From registry, included children with IHCA with an initial or subsequent shockable rhythm and then matched based on a propensity score

Paragraph 282 0
No paragraph-level conversations.
Paragraph 282, Sentence 1 0
No sentence-level conversations.

283 No difference between lidocaine and amiodarone for survival, ROSC, or favorable neuro outcome

Paragraph 283 0
No paragraph-level conversations.
Paragraph 283, Sentence 1 0
No sentence-level conversations.

284 Wang et al., 2020: Outcomes associated with amiodarone and lidocaine for the treatment for adult IHCA with shock refractory pulseless ventricular tachyarrhythmia

Paragraph 284 0
No paragraph-level conversations.
Paragraph 284, Sentence 1 0
No sentence-level conversations.

285 Included 130 patients with IHCA and VF/pVT requiring more than one defibrillation attempt

Paragraph 285 0
No paragraph-level conversations.
Paragraph 285, Sentence 1 0
No sentence-level conversations.

286 No control group. No difference in ROSC, survival or favorable neuro outcome for lidocaine v amiodarone.

Paragraph 286 0
No paragraph-level conversations.
Paragraph 286, Sentence 1 0
No sentence-level conversations.
Paragraph 286, Sentence 2 0
No sentence-level conversations.

287 Amino et al., 2015: Nifekalant hydrochloride and amiodarone hydrochloride result in similar improvements for 24 hours survival in CPA patients: the SOS-KANTO 2012 study

Paragraph 287 0
No paragraph-level conversations.
Paragraph 287, Sentence 1 0
No sentence-level conversations.

288 Enrolled 500 adults with OOHCA who used a single antiarrhythmic for shock resistant VF/VT. Survival to admission significantly higher with amiodarone and nifekalant compared to lidocaine and 24 hour survival. ROSC not different between groups

Paragraph 288 0
No paragraph-level conversations.
Paragraph 288, Sentence 1 0
No sentence-level conversations.
Paragraph 288, Sentence 2 0
No sentence-level conversations.
Paragraph 288, Sentence 3 0
No sentence-level conversations.

289 7 Experimental Studies

Paragraph 289 0
No paragraph-level conversations.
Paragraph 289, Sentence 1 0
No sentence-level conversations.

290 Ji et al., 2010: Comparison of the efficacy of nifekalant and amiodarone in a porcine model of cardiac arrest

Paragraph 290 0
No paragraph-level conversations.
Paragraph 290, Sentence 1 0
No sentence-level conversations.

291 4 minutes of untreated VF in 36 pigs randomized to amiodarone, placebo, or nifekalant. CPR initiated after drug admin and defibrillation attempted 2 minutes later

Paragraph 291 0
No paragraph-level conversations.
Paragraph 291, Sentence 1 0
No sentence-level conversations.
Paragraph 291, Sentence 2 0
No sentence-level conversations.

292 Nifekalant and amiodarone decreased number of shocks, defibrillation energy, epi dose, and duration of CPR. Higher ROSC and 24 hour survival in both groups. Improved postresuscitation myocardial dysfunction with treatment

Paragraph 292 0
No paragraph-level conversations.
Paragraph 292, Sentence 1 0
No sentence-level conversations.
Paragraph 292, Sentence 2 0
No sentence-level conversations.
Paragraph 292, Sentence 3 0
No sentence-level conversations.

293 Zoerner et al., 2014: Resuscitation with amiodarone increases survival after hemorrhage and VF in pigs

Paragraph 293 0
No paragraph-level conversations.
Paragraph 293, Sentence 1 0
No sentence-level conversations.

294 18 anesthetized piglets bled 30% blood volume to MAP of 35 mmHg followed by 4 minutes of VF and 11 minutes of open chest CPR. At 4 minutes received either amiodarone or saline. Both groups received hypertonic-hyperoncotic solution and vasopressin at this time. Defibrillation attempted from 7 min of cardiac arrest

Paragraph 294 0
No paragraph-level conversations.
Paragraph 294, Sentence 1 0
No sentence-level conversations.
Paragraph 294, Sentence 2 0
No sentence-level conversations.
Paragraph 294, Sentence 3 0
No sentence-level conversations.
Paragraph 294, Sentence 4 0
No sentence-level conversations.

295 ROSC effects did not achieve statistical significant difference. Pigs in control group needed more vasopressin doses to achieve ROSC

Paragraph 295 0
No paragraph-level conversations.
Paragraph 295, Sentence 1 0
No sentence-level conversations.
Paragraph 295, Sentence 2 0
No sentence-level conversations.

296 Karlis et al., 2015: Nifekalant versus amiodarone in the treatment of cardiac arrest: an experimental study in a swine model of prolonged VF

Paragraph 296 0
No paragraph-level conversations.
Paragraph 296, Sentence 1 0
No sentence-level conversations.

297 8 minutes of untreated VF followed by bolus of epi and either nifekalant, amiodarone, or saline in pigs. Then CPR and defibrillation after 2 minutes

Paragraph 297 0
No paragraph-level conversations.
Paragraph 297, Sentence 1 0
No sentence-level conversations.
Paragraph 297, Sentence 2 0
No sentence-level conversations.

298 Number of shocks needed, time to ROSC, and epi dose higher with amiodarone. No difference in 48 hour survival between control and amiodarone or ROSC

Paragraph 298 0
No paragraph-level conversations.
Paragraph 298, Sentence 1 0
No sentence-level conversations.
Paragraph 298, Sentence 2 0
No sentence-level conversations.

299 Stoner et al., 2003: Amiodarone and bretylium in the treatment of hypothermic VF in a canine model

Paragraph 299 0
No paragraph-level conversations.
Paragraph 299, Sentence 1 0
No sentence-level conversations.

300 30 dogs anesthetized, cooled, and VF induced. CPR initiated (no epi) and randomized to receive amiodarone, bretylium or placebo. After 10 minutes, up to three shocks administered

Paragraph 300 0
No paragraph-level conversations.
Paragraph 300, Sentence 1 0
No sentence-level conversations.
Paragraph 300, Sentence 2 0
No sentence-level conversations.
Paragraph 300, Sentence 3 0
No sentence-level conversations.

301 No difference in ROSC between groups

Paragraph 301 0
No paragraph-level conversations.
Paragraph 301, Sentence 1 0
No sentence-level conversations.

302 Wira et al., 2006: Application of normothermic cardiac arrest algorithms to hypothermic cardiac arrest in a canine model

Paragraph 302 0
No paragraph-level conversations.
Paragraph 302, Sentence 1 0
No sentence-level conversations.

303 21 dogs cooled to VF or VF induced if necessary. Treatment group received epi, defibrillation, and amiodarone. Not blinded

Paragraph 303 0
No paragraph-level conversations.
Paragraph 303, Sentence 1 0
No sentence-level conversations.
Paragraph 303, Sentence 2 0
No sentence-level conversations.
Paragraph 303, Sentence 3 0
No sentence-level conversations.

304 CPP increased with amiodarone/epi administration and improved ROSC

Paragraph 304 0
No paragraph-level conversations.
Paragraph 304, Sentence 1 0
No sentence-level conversations.

305 Anastasiou-Nana et al., 1994: Effects of amiodarone on refractory VF in acute myocardial infarction: experimental study

Paragraph 305 0
No paragraph-level conversations.
Paragraph 305, Sentence 1 0
No sentence-level conversations.

306 AMI induced in 60 dogs via ligation. Dogs that developed VF were treated with lidocaine, epi, and 5 shocks. Refractory dogs randomized to receive epi, lidocaine, and counter shocks or amiodarone and countershocks

Paragraph 306 0
No paragraph-level conversations.
Paragraph 306, Sentence 1 0
No sentence-level conversations.
Paragraph 306, Sentence 2 0
No sentence-level conversations.
Paragraph 306, Sentence 3 0
No sentence-level conversations.

307 Defibrillation significantly higher in amiodarone group

Paragraph 307 0
No paragraph-level conversations.
Paragraph 307, Sentence 1 0
No sentence-level conversations.

308 Wiesmann et al., 2017: Dantrolene versus amiodarone for CPR: a randomized double blinded experimental stuy

Paragraph 308 0
No paragraph-level conversations.
Paragraph 308, Sentence 1 0
No sentence-level conversations.

309 VF induced in anesthetized pigs. After 8 min untreated, CPR started and randomized to amiodarone, dantrolene, or slaine. After 4 minutes, defibrillation attempted

Paragraph 309 0
No paragraph-level conversations.
Paragraph 309, Sentence 1 0
No sentence-level conversations.
Paragraph 309, Sentence 2 0
No sentence-level conversations.
Paragraph 309, Sentence 3 0
No sentence-level conversations.

310 No difference in ROSC, persistent ROSC, or shocks until ROSC between groups

Paragraph 310 0
No paragraph-level conversations.
Paragraph 310, Sentence 1 0
No sentence-level conversations.

311 Outcome: Surrogate markers of perfusion

Paragraph 311 0
No paragraph-level conversations.
Paragraph 311, Sentence 1 0
No sentence-level conversations.

312 0 Clinical Trials

Paragraph 312 0
No paragraph-level conversations.
Paragraph 312, Sentence 1 0
No sentence-level conversations.

313 1 Observational Studies

Paragraph 313 0
No paragraph-level conversations.
Paragraph 313, Sentence 1 0
No sentence-level conversations.

314 Wang et al., 2020: Outcomes associated with amiodarone and lidocaine for the treatment for adult IHCA with shock refractory pulseless ventricular tachyarrhythmia

Paragraph 314 0
No paragraph-level conversations.
Paragraph 314, Sentence 1 0
No sentence-level conversations.

315 Included 130 patients with IHCA and VF/pVT requiring more than one defibrillation attempt

Paragraph 315 0
No paragraph-level conversations.
Paragraph 315, Sentence 1 0
No sentence-level conversations.

316 No control group. No difference in ROSC, survival or favorable neuro outcome for lidocaine v amiodarone. Amiodarone group experienced a higher likelihood of terminating VF/pVT within three shocks

Paragraph 316 0
No paragraph-level conversations.
Paragraph 316, Sentence 1 0
No sentence-level conversations.
Paragraph 316, Sentence 2 0
No sentence-level conversations.
Paragraph 316, Sentence 3 0
No sentence-level conversations.

317 11 Experimental Studies

Paragraph 317 0
No paragraph-level conversations.
Paragraph 317, Sentence 1 0
No sentence-level conversations.

318 Stoner et al., 2003: Amiodarone and bretylium in the treatment of hypothermic VF in a canine model

Paragraph 318 0
No paragraph-level conversations.
Paragraph 318, Sentence 1 0
No sentence-level conversations.

319 30 dogs anesthetized, cooled, and VF induced. CPR initiated (no epi) and randomized to receive amiodarone, bretylium or placebo. After 10 minutes, up to three shocks administered

Paragraph 319 0
No paragraph-level conversations.
Paragraph 319, Sentence 1 0
No sentence-level conversations.
Paragraph 319, Sentence 2 0
No sentence-level conversations.
Paragraph 319, Sentence 3 0
No sentence-level conversations.

320 Amiodarone lowered CPP but did not reach statistical significance

Paragraph 320 0
No paragraph-level conversations.
Paragraph 320, Sentence 1 0
No sentence-level conversations.

321 Wira et al., 2006: Application of normothermic cardiac arrest algorithms to hypothermic cardiac arrest in a canine model

Paragraph 321 0
No paragraph-level conversations.
Paragraph 321, Sentence 1 0
No sentence-level conversations.

322 21 dogs cooled to VF or VF induced if necessary. Treatment group received epi, defibrillation, and amiodarone. Not blinded

Paragraph 322 0
No paragraph-level conversations.
Paragraph 322, Sentence 1 0
No sentence-level conversations.
Paragraph 322, Sentence 2 0
No sentence-level conversations.
Paragraph 322, Sentence 3 0
No sentence-level conversations.

323 CPP increased with amiodarone/epi administration and improved ROSC

Paragraph 323 0
No paragraph-level conversations.
Paragraph 323, Sentence 1 0
No sentence-level conversations.

324 Ji et al., 2010: Comparison of the efficacy of nifekalant and amiodarone in a porcine model of cardiac arrest

Paragraph 324 0
No paragraph-level conversations.
Paragraph 324, Sentence 1 0
No sentence-level conversations.

325 4 minutes of untreated VF in 36 pigs randomized to amiodarone, placebo, or nifekalant. CPR initiated after drug admin and defibrillation attempted 2 minutes later

Paragraph 325 0
No paragraph-level conversations.
Paragraph 325, Sentence 1 0
No sentence-level conversations.
Paragraph 325, Sentence 2 0
No sentence-level conversations.

326 Nifekalant and amiodarone decreased number of shocks, defibrillation energy, epi dose, and duration of CPR. Improved postresuscitation myocardial dysfunction with treatment. Amiodarone decreased HR, arterial BP, and CPP

Paragraph 326 0
No paragraph-level conversations.
Paragraph 326, Sentence 1 0
No sentence-level conversations.
Paragraph 326, Sentence 2 0
No sentence-level conversations.
Paragraph 326, Sentence 3 0
No sentence-level conversations.

327 Glover et al., 2013: Dronedarone and captisol enabled amiodarone in an experimental cardiac arrest

Paragraph 327 0
No paragraph-level conversations.
Paragraph 327, Sentence 1 0
No sentence-level conversations.

328 42 pigs had induced VF, CPR for 3 minutes and then randomized to receive placebo, amiodarone, or dronedarone, followed by defibrillation and continued CPR

Paragraph 328 0
No paragraph-level conversations.
Paragraph 328, Sentence 1 0
No sentence-level conversations.

329 No effect on surrogate markers of perfusion

Paragraph 329 0
No paragraph-level conversations.
Paragraph 329, Sentence 1 0
No sentence-level conversations.

330 Anastasiou-Nana et al., 1994: Effects of amiodarone on refractory VF in acute myocardial infarction: experimental study

Paragraph 330 0
No paragraph-level conversations.
Paragraph 330, Sentence 1 0
No sentence-level conversations.

331 AMI induced in 60 dogs via ligation. Dogs that developed VF were treated with lidocaine, epi, and 5 shocks. Refractory dogs randomized to receive epi, lidocaine, and counter shocks or amiodarone and countershocks

Paragraph 331 0
No paragraph-level conversations.
Paragraph 331, Sentence 1 0
No sentence-level conversations.
Paragraph 331, Sentence 2 0
No sentence-level conversations.
Paragraph 331, Sentence 3 0
No sentence-level conversations.

332 Defibrillation significantly higher in amiodarone group. Worse markers of perfusion in amiodarone group

Paragraph 332 0
No paragraph-level conversations.
Paragraph 332, Sentence 1 0
No sentence-level conversations.
Paragraph 332, Sentence 2 0
No sentence-level conversations.

333 Karlis et al., 2015: Nifekalant versus amiodarone in the treatment of cardiac arrest: an experimental study in a swine model of prolonged VF

Paragraph 333 0
No paragraph-level conversations.
Paragraph 333, Sentence 1 0
No sentence-level conversations.

334 8 minutes of untreated VF followed by bolus of epi and either nifekalant, amiodarone, or saline in pigs. Then CPR and defibrillation after 2 minutes

Paragraph 334 0
No paragraph-level conversations.
Paragraph 334, Sentence 1 0
No sentence-level conversations.
Paragraph 334, Sentence 2 0
No sentence-level conversations.

335 Higher SAP, DAP, and CPP with nifekalant. Number of shocks needed, time to ROSC, and epi dose higher with amiodarone.

Paragraph 335 0
No paragraph-level conversations.
Paragraph 335, Sentence 1 0
No sentence-level conversations.
Paragraph 335, Sentence 2 0
No sentence-level conversations.

336 Zoerner et al., 2014: Resuscitation with amiodarone increases survival after hemorrhage and VF in pigs

Paragraph 336 0
No paragraph-level conversations.
Paragraph 336, Sentence 1 0
No sentence-level conversations.

337 18 anesthetized piglets bled 30% blood volume to MAP of 35 mmHg followed by 4 minutes of VF and 11 minutes of open chest CPR. At 4 minutes received either amiodarone or saline. Both groups received hypertonic-hyperoncotic solution and vasopressin at this time. Defibrillation attempted from 7 min of cardiac arrest

Paragraph 337 0
No paragraph-level conversations.
Paragraph 337, Sentence 1 0
No sentence-level conversations.
Paragraph 337, Sentence 2 0
No sentence-level conversations.
Paragraph 337, Sentence 3 0
No sentence-level conversations.
Paragraph 337, Sentence 4 0
No sentence-level conversations.

338 Greater 3 hour survival in amiodarone group; also had lower HR and better SAP, DAP, and MAP. Lower troponin I and higher UOP

Paragraph 338 0
No paragraph-level conversations.
Paragraph 338, Sentence 1 0
No sentence-level conversations.
Paragraph 338, Sentence 2 0
No sentence-level conversations.

339 Frame, 1989: The effect of chronic oral and acute IV amiodarone administration on ventricular defibrillation threshold using implanted electrodes in dogs

Paragraph 339 0
No paragraph-level conversations.
Paragraph 339, Sentence 1 0
No sentence-level conversations.

340 VF induced and then defibrillation following oral and IV amiodarone administration

Paragraph 340 0
No paragraph-level conversations.
Paragraph 340, Sentence 1 0
No sentence-level conversations.

341 Oral amiodarone increased the fibrillation threshold. No change with IV administration. Not directly relevant to PICO, but provides important info tangential to it (amiodarone probably does not make it harder to defibrillate)

Paragraph 341 0
No paragraph-level conversations.
Paragraph 341, Sentence 1 0
No sentence-level conversations.
Paragraph 341, Sentence 2 0
No sentence-level conversations.
Paragraph 341, Sentence 3 0
No sentence-level conversations.

342 Fain et al., 1987: Effects of acute IV and chronic oral amiodarone on defibrillation energy requirements

Paragraph 342 0
No paragraph-level conversations.
Paragraph 342, Sentence 1 0
No sentence-level conversations.

343 VF induced and then defibrillation following oral and IV amiodarone administration

Paragraph 343 0
No paragraph-level conversations.
Paragraph 343, Sentence 1 0
No sentence-level conversations.

344 Oral amiodarone increased the fibrillation threshold. No change with IV administration. Not directly relevant to PICO, but provides important info tangential to it (amiodarone probably does not make it harder to defibrillate)

Paragraph 344 0
No paragraph-level conversations.
Paragraph 344, Sentence 1 0
No sentence-level conversations.
Paragraph 344, Sentence 2 0
No sentence-level conversations.
Paragraph 344, Sentence 3 0
No sentence-level conversations.

345 Paiva et al, 2003: Effect of amiodarone on haemodynamics during CPR in a canine model of resistant VF

Paragraph 345 0
No paragraph-level conversations.
Paragraph 345, Sentence 1 0
No sentence-level conversations.

346 30 dogs with 8 minutes untreated VF, defibrillation attempted and CPR started. Resistant dogs randomized to epi, amiodarone, or both

Paragraph 346 0
No paragraph-level conversations.
Paragraph 346, Sentence 1 0
No sentence-level conversations.
Paragraph 346, Sentence 2 0
No sentence-level conversations.

347 SAP, DAP, and CPP all lower in amiodarone alone group

Paragraph 347 0
No paragraph-level conversations.
Paragraph 347, Sentence 1 0
No sentence-level conversations.

348 Arrendondo et al., 1986: Effect of amiodarone on ventricular fibrillation and defibrillation thresholds in the canine heart under normal and ischemic conditions

Paragraph 348 0
No paragraph-level conversations.
Paragraph 348, Sentence 1 0
No sentence-level conversations.

349 11 dogs with VF during control, drug (amiodarone), and coronary occlusion phases

Paragraph 349 0
No paragraph-level conversations.
Paragraph 349, Sentence 1 0
No sentence-level conversations.

350 Amiodarone led to successful defibrillation in 7/8 dogs compared to 1/7 in the control group P<0.005)

Paragraph 350 0
No paragraph-level conversations.
Paragraph 350, Sentence 1 0
No sentence-level conversations.

DMU Timestamp: July 13, 2023 21:18

General Document Comments 2

profile_photo
Jul 17
Rebecca W Rebecca W (Jul 17 2023 8:37PM) : The previous comment does not recommend lidocaine use and then this PICO starts with "if lidocaine is unavailable"
profile_photo
Jul 17
Dan F Dan F (Jul 17 2023 9:56PM) : Please clarify your question. [Edited]

Hi Rebecca! Can you please clarify what you mean by “the previous comment?” ALS-01 suggests that lidocaine can be used in dogs but probably shouldn’t be used in cats. This PICO suggests that if lidocaine is not available, you could use amiodarone in dogs, but lidocaine is preferred. Please let us know what you mean here. Thanks!

Image
0 comments, 0 areas
add area
add comment
change display
Video
add comment

Quickstart: Commenting and Sharing

How to Comment
  • Click icons on the left to see existing comments.
  • Desktop/Laptop: double-click any text, highlight a section of an image, or add a comment while a video is playing to start a new conversation.
    Tablet/Phone: single click then click on the "Start One" link (look right or below).
  • Click "Reply" on a comment to join the conversation.
How to Share Documents
  1. "Upload" a new document.
  2. "Invite" others to it.

Logging in, please wait... Blue_on_grey_spinner